Contract manufacturing of GMP drug substance and commercial-scale tablets to support the XRX-OXY-102 clinical study and future US FDA marketing approval...
Technology transfer to LyFE Manufacturing Center™ completed following FDA review of improved manufacturing process and updated analytical methods...
HOPE is the first Interventional Psychiatry network to deploy Zeta Surgical's newly FDA-cleared TMS Robotic System; the HOPE clinical team is completin...
Omniscient announced 510(k) clearance from the U.S. Food and Drug Administration for a new workflow within the Quicktome® platform: Quicktome Deep Br...
Lonza will build a new large-scale, commercial PSD-4 spray-drying facility in Bend, Oregon (US) to support a rapidly expanding market segment ...
If approved, Enspryng would be the first and only disease-modifying therapy for MOGAD (myelin oligodendrocyte glycoprotein antibody-associated diseas...
Leading nutraceutical contract manufacturer secures prime Irvine facility near John Wayne Airport, marking its tenth operational site and further elevati...
Detailed Phase 3 CANOPY-HCH-3 data in children living with hypochondroplasia also featured in a late-breaking oral presentation at th...
The POLARIS-1 study enrolled 147 patients with uncontrolled, moderate-to-severe asthma, and the interim analysis was conducted on the first 98 patients...
FDA sets Prescription Drug User Fee Act (PDUFA) date of March 10, 2027 Positions lonvo-z to be the world’s first in vivo CRISPR-based therapy an...
Agreement includes pre-payment commitments for product sales and distribution of the second-generation multi-cytokine-based HCW11-006 for use as a reagen...
-Aptar Pharma, a global leader in drug delivery, dosing, protection technologies and services, today announced a collaboration with Aceso Therapeutics, a...
HARBOR did not meet its primary endpoint of vHOT in DM1, a progressive neuromuscular disease with high unmet need and no approved treatment options ...
Early detection remains one of the biggest challenges in cancer care, particularly for ovarian cancer, where symptoms can be difficult to r...
© 2026 Biopharma Boardroom. All Rights Reserved.
